Written by Admin | Jun 9, 2017
A study published in the New England Journal of Medicine suggests that a new class of type 2 diabetes drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, may increase the risk of diabetic ketoacidosis.
Read More